| Item
7.01 | Regulation
FD Disclosure. |
On September 8, 2022, Bionik
Laboratories Corp. (the “Company”) issued a press release to announce the acquisition of a rehabilitation center in Clermont,
FL, the first in the Company’s planned strategic national rollout.
The center is revenue-producing,
profitable and has an existing roster of patients and referral sources. The Company intends for it to be rebranded to a specialized neuro-recovery
center that will showcase the Company’s technology and solutions, providing treatment to patients with stroke, brain and spinal
cord injuries, in addition to its historic treatment offerings. This first center will be named Tower Aquatic and be rebranded as a BIONIK
Company.
The Company financed the acquisition
of the rehabilitation center with a secured convertible loan from an existing investor of the Company who is also one of its directors,
as previously announced, indicating continuing support and belief in this new strategy.
The press release, which is
furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this report (including
Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed
an admission as to the materiality of any information herein (including Exhibit 99.1).
Forward-Looking Statements
Any statements contained in
this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements. Forward-looking statements,
which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words
"may," "should," "would," "will," "could," "scheduled," "expect,"
"anticipate," "estimate," "believe," "intend," "seek," or "project" or the
negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating
to the design, development and commercialization of robotic rehabilitation products and the roll-out of its recently-announced Neuro-Recovery
Centers of Excellence strategy, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital
expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial
performance, including as a result of the acquisition and rebranding of the Company’s Neuro-Recovery Centers of Excellence, and
the future financial performance of any such Centers of Excellence the Company may acquire or launch (iv) the market and projected market
for our existing and planned products and services and (v) the assumptions underlying or relating to any statement described in points
(i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events
or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations,
estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has
no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking
statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's
inability to obtain additional financing or increase revenue, the inability to meet listing standards to uplist to a national stock exchange,
the significant length of time and resources associated with the development and sale of our products and related insufficient cash flows
and resulting illiquidity, the continued impact on the Company’s business as a result of the Covid-19 pandemic, the Company's inability
to expand the Company's business, including its recently-launched Neuro-Recovery Centers of Excellence strategy, significant government
regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw
materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
